Clover Biopharmaceuticals Ltd (2197.HK)
Company Info
| ISIN | KYG2280A1076 |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
Highlights
| Market Cap | HK$1.58B |
|---|---|
| EPS | HK$0.00 |
| PE Ratio | N/A |
| PEG Ratio | N/A |
| Revenue (TTM) | HK$0.00 |
| Gross Profit (TTM) | -HK$475.64M |
| EBITDA (TTM) | -HK$2.34B |
| Year Range | HK$1.12 - HK$6.09 |
| Target Price | HK$3.66 |
Share Price Chart
Loading data...
Performance
The chart shows the growth of an initial investment of HK$10,000 in Clover Biopharmaceuticals Ltd, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Compare to other instruments
Return
Clover Biopharmaceuticals Ltd had a return of -56.37% year-to-date (YTD) and -71.32% in the last 12 months. Over the past 10 years, Clover Biopharmaceuticals Ltd had an annualized return of -79.77%, outperforming the S&P 500 benchmark which had an annualized return of -7.44%.
| Period | Return | Benchmark |
|---|---|---|
| 1 month | -35.06% | 0.91% |
| Year-To-Date | -56.37% | 7.82% |
| 6 months | -75.91% | 2.41% |
| 1 year | -71.32% | -2.53% |
| 5 years (annualized) | -79.77% | -7.44% |
| 10 years (annualized) | -79.77% | -7.44% |
Monthly Returns Heatmap
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | -2.32% | -1.19% | -35.20% | 14.20% | -38.38% | |||||||
| 2022 | 203.31% | -52.82% |
Risk-Adjusted Performance
This table presents a comparison of risk-adjusted performance metrics for Clover Biopharmaceuticals Ltd (2197.HK) and S&P 500 (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| Sharpe ratio | Sortino ratio | Omega ratio | Calmar ratio | Ulcer Index | |
|---|---|---|---|---|---|
2197.HK Clover Biopharmaceuticals Ltd | -0.74 | ||||
^GSPC S&P 500 | 0.10 |
Dividend History
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below shows the maximum drawdowns of the Clover Biopharmaceuticals Ltd. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.
The maximum drawdown since January 2010 for the Clover Biopharmaceuticals Ltd is 92.03%, recorded on Jun 1, 2023. The portfolio has not recovered from it yet.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -92.03% | Dec 14, 2021 | 359 | Jun 1, 2023 | — | — | — |
| -29.97% | Nov 8, 2021 | 3 | Nov 10, 2021 | 21 | Dec 9, 2021 | 24 |
Volatility Chart
The current Clover Biopharmaceuticals Ltd volatility is 22.62%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.